Why Top Investors Are Buying Danaher (DHR)

In the most recently reported quarter, several renowned institutional investors made notable increases to their Danaher (DHR) holdings, reflecting growing confidence in the life sciences and diagnostics conglomerate. As the company continues to evolve its portfolio through innovation and strategic divestitures, Danaher is attracting fresh institutional capital as a long-term compounder in the healthcare sector.

Let’s examine some of the most significant moves:

---

Maverick Capital (Lee Ainslie)
Shares: 698,740
Change: NEW POSITION
Value: $0.14B

Lee Ainslie initiated a new position in DHR, suggesting a fresh thesis forming around the company’s innovation pipeline and long-term secular tailwinds in biotech and diagnostics. Maverick’s move could be an early signal of deeper conviction to come.

---

Viking Global Investors (Andreas Halvorsen)
Shares: 451,521
Change: NEW POSITION
Value: $0.09B

Andreas Halvorsen entered a new stake in Danaher, possibly seeing a high-quality compounder trading at an attractive valuation. Viking is known for concentrated positions in durable, fundamentally sound businesses, making this new entry a notable endorsement of DHR’s long-term potential.

---

AQR Capital Management (Cliff Asness)
Shares: 747,389
Change: ↑ +370,483 (Previously: 376,906)
Value: $0.15B

Cliff Asness’s AQR nearly doubled its position in DHR this quarter. AQR’s factor-based approach typically emphasizes valuation, quality, and momentum—traits that may be resurfacing in Danaher as it stabilizes post-COVID testing decline and refocuses on core diagnostics and bioprocessing.

---

Fisher Asset Management (Ken Fisher)
Shares: 4,635,128
Change: ↑ +56,183 (Previously: 4,578,945)
Value: $0.95B

Ken Fisher made a modest but meaningful addition to an already large position in Danaher. Fisher’s firm often favors high-quality companies with strong cash flow and defensible competitive moats—hallmarks of DHR’s long-standing acquisition-driven model.

---

Gotham Asset Management (Joel Greenblatt)
Shares: 73,602
Change: ↑ +16,559 (Previously: 57,043)
Value: $0.02B

Greenblatt’s increase signals renewed interest in DHR’s value proposition. Known for a strict adherence to earnings yield and return on capital, Gotham may be viewing DHR’s recent valuation compression as an opportunity to accumulate a compounder at a discount.

---

Grantham, Mayo, Van Otterloo & Co. (Jeremy Grantham)
Shares: 5,734
Change: ↑ +517 (Previously: 5,217)
Value: $0.00B

Though a small stake in absolute terms, the increase from GMO highlights continued interest in high-quality names with pricing power and global reach—two of Danaher’s enduring strengths.